Skip to main content
Premium Trial:

Request an Annual Quote

Tataa Biocenter Inks Licensing Deal with INSERM for ValidPrime Technology

NEW YORK (GenomeWeb) – Tataa Biocenter today announced it has signed an exclusive agreement to license the French Institute for Health and Medical Research's (INSERM) ValidPrime qPCR assay correction technology.

ValidPrime is a tool used to measure and compensate for the genomic DNA background signal in qPCR-based gene expression measurements. The technology "accurately corrects all reactions in high-throughput qPCR BioMark arrays for signals derived from gDNA," Vlasta Korenkova, head of Tataa's Prague facility, said in a statement.

ValidPrime is an alternative to performing extra control measurements needed to eliminate the gDNA background noise, and "in our high-throughput measurements, we save up to 95 percent of reagent cost and data are of excellent quality," Korenkova said.

ValidPrime is also used to standardize analyses of cell-free DNA, Göteborg, Sweden-based Tataa, a genomic services firm, said.

Financial and other terms of the agreement were not disclosed. 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.